Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
, 149 (12), 1730-1

Side Effects and the "Blindability" of Clinical Drug Trials

Multicenter Study

Side Effects and the "Blindability" of Clinical Drug Trials

K White et al. Am J Psychiatry.


A novel, simple approach to retrospective assessment of "blindability" was applied to data on outpatients in a controlled, double-blind clinical comparison of a putative antidepressant, etoperidone, and placebo. A "blind" evaluator proved capable of discriminating between the active drug and placebo on the basis of reported side effects alone, raising questions about the true blindness of the study.

Comment in

Similar articles

  • Inert Placebo Versus Active Medication. Patient Blindability in Clinical Pharmacological Trials
    A Bystritsky et al. J Nerv Ment Dis 182 (9), 485-7. PMID 8083675. - Clinical Trial
    Patient blindability was examined in clinical, psychopharmacological, double-blind, placebo-controlled trials involving medications for obsessive-compulsive disorder and …
  • Trazodone in Depressed Outpatients
    K Rickels et al. Am J Psychiatry 139 (6), 803-6. PMID 7044154. - Clinical Trial
    The authors compared the nontricyclic antidepressant trazodone with amitriptyline and placebo in a double-blind study of 202 unipolar depressed outpatients. Trazodone's c …
  • A Double-Blind, Placebo-Controlled Trial of Fluvoxamine Versus Imipramine in Outpatients With Major Depression
    JS March et al. J Clin Psychiatry 51 (5), 200-2. PMID 2110560. - Clinical Trial
    The authors employed a double-blind, placebo-controlled design to investigate the effectiveness of fluvoxamine versus imipramine in 54 outpatients with moderate major dep …
  • Recent Experience With Trazodone
    M Lader. Psychopathology 20 Suppl 1, 39-47. PMID 3321129. - Review
    Trazodone is an atypical antidepressant with additional anxiolytic effects. Recent European experience with trazodone is reviewed with respect to antidepressant efficacy, …
  • Antidepressant Properties of Trazodone
    SG Bryant et al. Clin Pharm 1 (5), 406-17. PMID 6764164. - Review
    The chemistry, pharmacokinetics, biochemistry and pharmacology, clinical trials, adverse effects, FDA-approved indications, and availability and cost of trazodone hydroch …
See all similar articles

Cited by 6 PubMed Central articles

See all "Cited by" articles

Publication types

LinkOut - more resources